Hester Biosciences has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Friday, May 15, 2026. The intimation was issued on May 8, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).

Board Meeting Agenda

The Board meeting has been convened to address key financial and shareholder matters. The following agenda items have been disclosed in the official intimation:

• Audited Standalone Financial Results: Consideration of the audited standalone financial results for the quarter and year ended March 31, 2026.
• Audited Consolidated Financial Results: Consideration of the audited consolidated financial results for the quarter and year ended March 31, 2026.
• Dividend Declaration: Consideration of the declaration of dividend, if any, on the equity shares of the Company for the financial year 2025-26.

Meeting Details

The key details of the scheduled Board meeting are summarised below:

Company Details

Hester Biosciences is headquartered at Village Meda-Adraj, Taluka Kadi, District Mehsana, Gujarat. The official intimation to the exchanges was signed by Vinod Mali, Company Secretary & Compliance Officer, on May 8, 2026.

Hester Biosciences Limited has submitted a mandatory regulatory declaration confirming that its promoters and promoter group did not create any encumbrances on their shareholdings during the financial year ended March 31, 2026. The declaration was filed with both BSE and NSE on April 3, 2026, in compliance with SEBI regulations.

Regulatory Compliance Declaration

The company filed the declaration pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates that promoters and promoter groups must declare annually whether they have created any encumbrances on their shareholdings during the financial year.

Promoter Group Representative

Mr. Rajiv Gandhi submitted the declaration on behalf of the promoters and promoter group. In his communication to the stock exchanges, he confirmed that during the financial year ended March 31, 2026, no encumbrances were made on promoter holdings, either directly or indirectly.

The declaration also requested that this disclosure be presented to the company's Audit Committee for their review and comments, ensuring proper internal governance oversight.

Stock Exchange Communication

The company's Company Secretary and Compliance Officer, Vinod Mali, formally communicated the declaration to both major stock exchanges where Hester Biosciences shares are listed.

Corporate Governance Significance

This annual declaration forms part of the regulatory framework designed to ensure transparency in promoter shareholding patterns. The requirement helps investors and regulators monitor any changes in promoter commitment to their shareholdings through encumbrances such as pledging or hypothecation of shares.

The timely filing of this declaration demonstrates Hester Biosciences' commitment to regulatory compliance and corporate governance standards. Such disclosures are essential for maintaining investor confidence and ensuring transparency in promoter shareholding arrangements.